Two scientists from U.S. and one from Britain share Nobel Medicine Prize

Two scientists from the United States and one from Britain won the 2019 Nobel Medicine Prize on Monday for finding how cells adapt to fluctuating oxygen levels, paving the way for new strategies to fight diseases such as anemia and cancer.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news

Related Links:

AbstractThere is still uncertainty about the optimal usage of thrombolysis for acute pulmonary embolisms (PEs), leading to a widely varying usage in the real world. The COMMAND VTE Registry is a multicenter retrospective registry enrolling consecutive patients with acute symptomatic venous thromboembolisms (VTEs) in Japan. The present study population consisted of 1549 patients with PEs treated with tissue plasminogen activator (t-PA) thrombolysis (N  = 180, 12%) or without thrombolysis (N = 1369). Thrombolysis with t-PA was implemented in 33% of patients with severe PEs, and 9.2% of patients wi...
Source: Journal of Thrombosis and Thrombolysis - Category: Hematology Source Type: research
Acute myeloid leukemia (AML) represents 80% of adult leukemias and 15–20% of childhood leukemias. AML are characterized by the presence of 20% blasts or more in the bone marrow, or defining cytogenetic abnormalities. Laboratory diagnoses of myelodysplastic syndromes (MDS) depend on morphological changes based on dysplasia in peripheral blood and bone marrow, including peripheral blood smears, bone marrow aspirate smears, and bone marrow biopsies. As leukemic cells are not functional, the patient develops anemia, neutropenia, and thrombocytopenia, leading to fatigue, recurrent infections, and hemorrhage. The genetic b...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
ConclusionsThe exposure –response analysis suggested that intermittent 7-day veliparib 120 mg BID dosing in a 21-day cycle provided additional efficacy without meaningfully impacting the safety and tolerability when co-administered with carboplatin and paclitaxel in patients with BRCA-deficient breast cancer. A higher d ose of veliparib is unlikely to provide greater benefit in this combination in patients with BRCA-deficient recurrent or metastatic breast cancer.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
Conditions:   Aplastic Anemia;   Paroxysmal Nocturnal Hemoglobinuria Interventions:   Other: symptom questionnaire;   Other: recording of vital signs;   Other: European Organisation for Research and Treatment of Cancer (EORTC) quality of life questionnaire (QLQ)-C30 questionnaire;   Other: interview Sponsors:   University Hospital, Basel, Switzerland;   ProPatient foundation of the University Hospital Basel;   Novartis Not yet recruiting
Source: - Category: Research Source Type: clinical trials
In this study, in vitro evaluation of anti-tumor and anti-angiogenic activities of NS, MTX, or their mixture in different concentrations using liver hepatocellular carcinoma and endothelial cells were performed. The protective effects of NS on normal hepatic and kidney cells against the risks of MTX treatment was also tested in vitro. Moreover, for in vivo evaluation, male Wistar rats were treated with MTX or a combination of MTX and NS. Hematological and serological, biochemical, functional, and histopathological studies were performed. The results showed that the low concentration of NS enhanced the anti-tumor and anti-a...
Source: Comparative Clinical Pathology - Category: Pathology Source Type: research
Conclusion: Data from our study suggest nivolumab is well-tolerated and effective in Indian patients with recurrent advanced NSCLC after failure of the multiple first lines of platinum-based combination chemotherapy.
Source: Indian Journal of Cancer - Category: Cancer & Oncology Authors: Source Type: research
Triple-negative breast cancer (TNBC) is associated with worse prognosis, with limited treatment regiments available and higher mortality rate. Immune checkpoint inhibitors targeting programmed cell death-1 (PD-1) or programmed cell death-ligand 1 (PD-L1) showed great potentials in treating malignancies and may serve as potential therapies for TNBC. This systematic review aims to evaluate the efficacy and safety profiles of PD-1/PD-L1 inhibitors in the treatment of TNBC. Literature search was performed via PubMed, EBSCOhost, Scopus, and CENTRAL databases, selecting studies which evaluated the use of anti-PD-1/PD-L1 for TNBC...
Source: Oncology Reviews - Category: Cancer & Oncology Source Type: research
This article examines the recently published guidelines for ESA use in cancer patients from the American Society of Clinical Oncology and American Society of Hematology and attempts to contextualize them to the care of patients with coexistent CKD, cancer, and anemia. PMID: 31596520 [PubMed - as supplied by publisher]
Source: Seminars in Dialysis - Category: Urology & Nephrology Authors: Tags: Semin Dial Source Type: research
Companies are trying to make drugs to alter oxygen sensing in cancer and anemia
Source: Chemical and Engineering News - Category: Chemistry Authors: Source Type: research
Companies are trying to make drugs to alter oxygen sensing in cancer and anemia
Source: Chemical and Engineering News - Category: Chemistry Authors: Source Type: research
More News: Anemia | Cancer | Cancer & Oncology | Health | UK Health | USA Health